Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02726490 · ClinicalTrials.gov registry record · Early Phase 1
Glyburide vs Glucovance in the Treatment of GDM
A Early Phase 1 study, sponsored by Texas Tech University Health Sciences Center, El Paso.
- Terminated
- Registry status
- Early Phase 1
- Development phase
- 7
- Enrollment target
NCT02726490 is a Early Phase 1 study that was terminated before completion, run by Texas Tech University Health Sciences Center, El Paso. The registered enrollment target is 7 participants.
The verdict
NCT02726490, a Early Phase 1 study, was terminated before completion, sponsored by Texas Tech University Health Sciences Center, El Paso.
- TERMINATED
- Registry status
- Early Phase 1
- Development phase
- 7 participants
- Enrollment target
Study Summary
A randomized comparison of glyburide to glucovance (metformin -glyburide) in the management of diabetes in pregnancy.
Interventions
- DRUG Glyburide
- DRUG Glucovance
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 7 participants |
| Start Date | 2016-07 |
| Est. Completion | 2018-08-14 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02726490
The ClinicalTrials.gov registry entry for NCT02726490 describes a study currently listed as terminated, categorized as Early Phase 1. The registered enrollment target is 7 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Texas Tech University Health Sciences Center, El Paso, which has 35 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Glyburide is the first listed.
NCT02726490 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02726490 about?
NCT02726490 is a clinical study titled "Glyburide vs Glucovance in the Treatment of GDM". A randomized comparison of glyburide to glucovance (metformin -glyburide) in the management of diabetes in pregnancy.
What is the current status of trial NCT02726490?
This trial is currently terminated. It is a Early Phase 1 study. The enrollment target is 7 participants. The study started on 2016-07. Estimated completion is 2018-08-14.
What interventions are being tested in trial NCT02726490?
The interventions under investigation include: Glyburide (DRUG), Glucovance (DRUG).
Who is sponsoring clinical trial NCT02726490?
This trial is sponsored by Texas Tech University Health Sciences Center, El Paso, which has 35 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.